Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Katharina Kaltseis"'
Autor:
Benoît Bernar, Nina Gande, Anna Katharina Stock, Anna Staudt, Raimund Pechlaner, Christoph Hochmayr, Katharina Kaltseis, Bernhard Winder, Sophia Julia J. Kiechl, Gregor Broessner, Ralf Geiger, Stefan Kiechl, Early Vascular Ageing (EVA) Tyrol Study Group, Ursula Kiechl-Kohlendorfer, Michael Knoflach
Publikováno v:
BMC Cardiovascular Disorders, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Migraine with aura is associated with an increased risk of cardiovascular disease, yet the pathophysiology is unknown. Suggested underlying mechanisms of aura formation point into the direction of an abnormal vasoreactivity that a
Externí odkaz:
https://doaj.org/article/b2881ff8e29c45ed821b18245f5d3c77
Autor:
Katharina Kaltseis, Vera Filippi, Florian Frank, Christine Eckhardt, Alois Schiefecker, Gregor Broessner
Publikováno v:
BMC Neurology, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Objective Assessement of the responder and non-responder rate to consecutive monoclonal CGRP-antibody (CGRP-mAb) treatment, the presence of side effects, analysis of predictors of response and loss-of-effectiveness evaluation over time. Meth
Externí odkaz:
https://doaj.org/article/f4f5cf20e90b48aba90ff8c303226ab4
Publikováno v:
Cephalalgia Reports, Vol 6 (2023)
Background: Primary stabbing headache (PSH) is a rare primary headache presenting with short, stabbing pain sensations of unknown etiology. Owed to the rare prevalence of the disease, only limited data exists on possible treatment options. The most c
Externí odkaz:
https://doaj.org/article/e0092050de254daeab2de6161cff5391
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
BackgroundThere is a growing body of mitochondrial disorders that are associated with headaches, albeit only one of them is currently listed in the latest International Classification of Headache Disorders, 3rd edition (ICHD-3). Headache frequency an
Externí odkaz:
https://doaj.org/article/d9c7f9b834de4bd4bbc8268a67657720
Publikováno v:
Frontiers in Physiology, Vol 13 (2022)
Experimental models of human diseases are vital for pathophysiological and therapeutic research. To investigate the initiation, maintenance, pathophysiology and even termination of a migraine/headache attack these models are urgently needed. Results
Externí odkaz:
https://doaj.org/article/33e41fbacea54d9e9266a601ad5cf60b
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
BackgroundCalcitonin gene related peptide (CGRP) plays a key role in the pathophysiology of migraine and is therefore considered a potential biomarker for primary headache disorders. The challenge remaining is establishing standardized protocols for
Externí odkaz:
https://doaj.org/article/7abebc911ca64d169e2a5ed5da6ea6a8
Autor:
Vera Filippi, Ruth Steiger, Vincent Beliveau, Florian Frank, Katharina Kaltseis, Elke R. Gizewski, Gregor Broessner
Publikováno v:
Brain Sciences, Vol 12, Iss 5, p 646 (2022)
Recent neuroimaging studies have revealed important aspects of the underlying pathophysiological mechanisms of migraine suggesting abnormal brain energy metabolism and altered functional connectivity. Proton magnetic resonance spectroscopy (1H-MRS) s
Externí odkaz:
https://doaj.org/article/03326af85a4747839d3e86d38cdd07c5
Primary headache disorders in adolescents in North- and South-Tyrol: Findings of the EVA-Tyrol-Study
Autor:
Katharina, Kaltseis, Florian, Frank, Benoît, Bernar, Sophia, Kiechl, Bernhard, Winder, Ursula, Kiechl-Kohlendorfer, Michael, Knoflach, Gregor, Broessner
Publikováno v:
Cephalalgia. 42:993-1004
Objective Assessment of the prevalence of primary headache disorders, associated risk factors and use of acute/preventive medication in a representative large sample of adolescents. Methods Within the EVA-Tyrol project, a community-based non-randomiz
Publikováno v:
HeadacheREFERENCES. 62(10)
Along with the development of novel migraine therapies as the monoclonal antibodies against calcitonin gene-related peptide (CGRP) and its receptor, the question arises if the treatment of chronic migraine (CM) and medication overuse headache (MOH) m
Autor:
Katharina Kaltseis, Vera Filippi, Florian Frank, Christine Eckhardt, Alois Schiefecker, Gregor Broessner
ObjectiveAssessement of the responder and non-responder rate to consecutive monoclonal CGRP-antibody (CGRP-mAb) treatment, the presence of side effects, analysis of predictors of response and loss of efficacy evaluation over time. Methods We conducte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4f25f9fdae3257995784c3ae7fdcdf0
https://doi.org/10.21203/rs.3.rs-1843732/v1
https://doi.org/10.21203/rs.3.rs-1843732/v1